HNGE:NYSEHinge Health, Inc. Analysis

Hinge Health posted a *47% year‑over‑year revenue surge* to $182.3 M in Q1 2026 and generated $46 M of operating income, delivering a **25% operating margin**—a sharp turnaround from prior losses. The company’s forward PE of **17.7** sits well below the health‑information services industry average of **27.6**, while the DCF‑derived fair value of **$209** suggests the stock is **substantially undervalued** relative to its current price of $55.25. Technicals show the price trading near the **$56.5 resistance**, with an **RSI of 72** indicating overbought conditions and a **bearish MACD histogram**, hinting at short‑term pressure. Nevertheless, the firm boasts a strong cash position of $315.9 M, minimal debt, and a **beta of 1.43** that reflects higher-than‑market volatility (30‑day volatility ~46% and a max drawdown of –48%).
The upbeat earnings beat, aggressive 2026 revenue guidance of $798‑$804 M, and the launch of an FDA‑cleared migraine program underpin a compelling growth narrative. While liquidity is moderate and volume trends are decreasing, the combination of robust top‑line growth, improving profitability, and a valuation gap supports a **buy** stance for medium‑ and long‑term horizons, with a cautious **hold** recommendation in the immediate term.